In the management of allergic rhinitis, drugs are delivered to the nasal cavity for a local effect. Mucociliary clearance (MC), the airway’s primary innate defense mechanism against inhaled foreign particles, clears the drug formulations and undesirably decreases their residence time. Certain formulation variables are hence designed to optimize the intranasal (IN) residence time. It is therefore important that the effect of IN formulations on MC is understood. MC is attained via ciliary input (cilia length and density and ciliary beat frequency (CBF)) and airway surface liquid (periciliary fluid underlying mucous blanket of optimum amount, depth and viscoelastic properties). In the present study, ovine ex-vivo models were used to investigate the effect of a number of anti-allergic IN formulations, by GlaxoSmithKline (GSK), on different components of MC, namely mucin secretion, CBF and mucociliary transport rate (MTR). In addition, the in-vitro cytotoxic effect of these formulations on the human bronchial epithelial cell line, 16HBE14o-, was examined using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide) viability assay.